Please assess the completion status of the following clinical trial:

Trial Title: A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of migraine or chronic migraine.~* History of migraine headaches at least 1 year prior to screening, with onset prior to age 50.~* History of at least 4 migraine headache days and at, with at least 1 headache-free day per month on average within the past 3 months.~* Have documentation of 2 to 4 migraine preventive medication category failures due to inadequate efficacy or tolerability, in the past 10 years.~Exclusion Criteria:~* Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.~* Current use or prior exposure to galcanezumab or another calcitonin gene-related peptide (CGRP) antibody.~* History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine).~* Pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Galcanezumab (Type: EXPERIMENTAL): Galcanezumab administered subcutaneously (SC).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC.

Based on this trial design, predict the completion outcome and termination type (if applicable).